{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:20:47Z","timestamp":1790371247505,"version":"4.1.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s42000-024-00588-1","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T16:04:36Z","timestamp":1723046676000},"page":"621-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Angeliki","family":"Katsarou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsioulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Chatzigeorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"9","key":"588_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"588_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"issue":"1","key":"588_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2017.08.001","volume":"22","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Henry L, Bush H, Mishra A (2018) Clinical and economic burden of nonalcoholic fatty liver disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 22(1):1\u201310. https:\/\/doi.org\/10.1016\/j.cld.2017.08.001","journal-title":"Clin Liver Dis"},{"key":"588_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol S016882782300418X. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol S016882782300418X"},{"issue":"5","key":"588_CR5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"2","key":"588_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000443344","volume":"9","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts 9(2):65\u201390. https:\/\/doi.org\/10.1159\/000443344","journal-title":"Obes Facts"},{"issue":"10390","key":"588_CR7","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, De Gaetano A, Lembo E, Capristo E et al (2023) Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 401(10390):1786\u20131797. https:\/\/doi.org\/10.1016\/S0140-6736(23)00634-7","journal-title":"Lancet"},{"key":"588_CR8","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med 21;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"11","key":"588_CR9","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(11):2753\u20132786. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"588_CR10","unstructured":"FDA (2005) Approval package for Byetta injection 250mcg\/ml. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_Byetta_approv.PDF. Accessed 8 July 2023"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","volume":"58","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS (2023) Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine 58:101882. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101882","journal-title":"eClinicalMedicine"},{"issue":"4","key":"588_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli A, Cusi K (2019) From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep 1(4):312\u2013328. https:\/\/doi.org\/10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"issue":"12","key":"588_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","volume":"2","author":"H Halawi","year":"2017","unstructured":"Halawi H, Khemani D, Eckert D, O\u2019Neill J, Kadouh H, Grothe K et al (2017) Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol 2(12):890\u2013899. https:\/\/doi.org\/10.1016\/S2468-1253(17)30285-6","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"588_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","volume":"24","author":"R Nevola","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R et al (2023) GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. IJMS 24(2):1703. https:\/\/doi.org\/10.3390\/ijms24021703","journal-title":"IJMS"},{"issue":"6","key":"588_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/dmrr.2561","volume":"30","author":"N Shao","year":"2014","unstructured":"Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W (2014) Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes: Exenatide on obesity and Steatohepatitis. Diabetes Metab Res Rev 30(6):521\u2013529. https:\/\/doi.org\/10.1002\/dmrr.2561","journal-title":"Diabetes Metab Res Rev"},{"issue":"10019","key":"588_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"12","key":"588_CR17","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","volume":"59","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Pouwels PJW, Pieters-van Den Bos IC et al (2016) Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia 59(12):2588\u20132593. https:\/\/doi.org\/10.1007\/s00125-016-4100-7","journal-title":"Diabetologia"},{"issue":"3","key":"588_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","volume":"64","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami M, Minami I et al (2017) Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J 64(3):269\u2013281. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0449","journal-title":"Endocr J"},{"issue":"6","key":"588_CR19","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T et al (2019) Liraglutide, Sitagliptin, and insulin glargine added to Metformin: the Effect on Body Weight and Intrahepatic lipid in patients with type 2 diabetes Mellitus and nonalcoholic fatty liver disease. Hepatology 69(6):2414\u20132426. https:\/\/doi.org\/10.1002\/hep.30320","journal-title":"Hepatology"},{"issue":"5","key":"588_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/liv.14065","volume":"39","author":"J Khoo","year":"2019","unstructured":"Khoo J, Hsiang JC, Taneja R, Koo S, Soon G, Kam CJ et al (2019) Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int 39(5):941\u2013949. https:\/\/doi.org\/10.1111\/liv.14065","journal-title":"Liver Int"},{"issue":"12","key":"588_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V et al (2021) A placebo-controlled trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"10","key":"588_CR22","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M et al (2019) Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open 2(10):e1912565. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12565","journal-title":"JAMA Netw Open"},{"issue":"2","key":"588_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R et al (2022) Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. JAMA 327(2):138. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"issue":"6","key":"588_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1 (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"588_CR25","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1210\/jc.2016-1933","volume":"101","author":"M Asmar","year":"2016","unstructured":"Asmar M, Simonsen L, Asmar A, Holst JJ, Dela F, B\u00fclow J (2016) Insulin plays a permissive role for the Vasoactive Effect of GIP regulating adipose tissue metabolism in humans. J Clin Endocrinol Metabolism 101(8):3155\u20133162. https:\/\/doi.org\/10.1210\/jc.2016-1933","journal-title":"J Clin Endocrinol Metabolism"},{"key":"588_CR26","unstructured":"Buntz B (2024) GLP-1 drugs could open a new frontier in NASH treatment https:\/\/www.drugdiscoverytrends.com\/glp-1-drugs-could-open-a-new-frontier-in-nash-treatment\/. Accessed 7 April 2024"},{"issue":"11","key":"588_CR27","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G et al (2023) Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 29(11):2909\u20132918. https:\/\/doi.org\/10.1038\/s41591-023-02597-w","journal-title":"Nat Med"},{"issue":"6","key":"588_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK et al (2021) Tirzepatide versus Semaglutide once Weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"588_CR29","unstructured":"FDA (2022) FDA Approves Treatment for Wider Range of Patients with Heart Failure https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-wider-range-patients-heart-failure. Accessed 18 August 2023"},{"issue":"4","key":"588_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/jgh.15202","volume":"36","author":"L Chrysavgis","year":"2021","unstructured":"Chrysavgis L, Papatheodoridi A, Chatzigeorgiou A, Cholongitas E (2021) The impact of sodium glucose co-transporter 2 inhibitors on non\u2010alcoholic fatty liver disease. J Gastroenterol Hepatol 36(4):893\u2013909. https:\/\/doi.org\/10.1111\/jgh.15202","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"588_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/dom.14670","volume":"24","author":"S Kahl","year":"2022","unstructured":"Kahl S, Ofstad AP, Zinman B, Wanner C, Sch\u00fcler E, Sattar N et al (2022) Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metabolism 24(6):1061\u20131071. https:\/\/doi.org\/10.1111\/dom.14670","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"588_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H et al (2022) Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun 6(1):120\u2013132. https:\/\/doi.org\/10.1002\/hep4.1696","journal-title":"Hepatol Commun"},{"issue":"2","key":"588_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T et al (2019) Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21(2):285\u2013292. https:\/\/doi.org\/10.1111\/dom.13520","journal-title":"Diabetes Obes Metab"},{"key":"588_CR34","doi-asserted-by":"publisher","first-page":"1182037","DOI":"10.3389\/fendo.2023.1182037","volume":"14","author":"T Kongmalai","year":"2023","unstructured":"Kongmalai T, Srinonprasert V, Anothaisintawee T, Kongmalai P, McKay G, Attia J et al (2023) New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol 14:1182037. https:\/\/doi.org\/10.3389\/fendo.2023.1182037","journal-title":"Front Endocrinol"},{"issue":"9","key":"588_CR35","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnstr\u00f6m M, Moris L et al (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61(9):1923\u20131934. https:\/\/doi.org\/10.1007\/s00125-018-4675-2","journal-title":"Diabetologia"},{"key":"588_CR36","doi-asserted-by":"publisher","first-page":"836455","DOI":"10.3389\/fendo.2022.836455","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu X, Zhang H, Wang X (2022) Efficacy and safety of Empagliflozin on nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Front Endocrinol (Lausanne) 13:836455. https:\/\/doi.org\/10.3389\/fendo.2022.836455","journal-title":"Front Endocrinol (Lausanne)"},{"key":"588_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.18433\/jpps29831","volume":"21","author":"B Li","year":"2018","unstructured":"Li B, Wang Y, Ye Z, Yang H, Cui X, Wang Z et al (2018) Effects of Canagliflozin on fatty liver indexes in patients with type 2 diabetes: a Meta-analysis of Randomized controlled trials. J Pharm Pharm Sci 21:222\u2013235. https:\/\/doi.org\/10.18433\/jpps29831","journal-title":"J Pharm Pharm Sci"},{"issue":"11","key":"588_CR38","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1210\/clinem\/dgad249","volume":"108","author":"AN Borisov","year":"2023","unstructured":"Borisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F (2023) Canagliflozin and Metabolic Associated fatty liver disease in patients with diabetes Mellitus: New insights from CANVAS. J Clin Endocrinol Metabolism 108(11):2940\u20132949. https:\/\/doi.org\/10.1210\/clinem\/dgad249","journal-title":"J Clin Endocrinol Metabolism"},{"key":"588_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","volume":"136","author":"KHH Liss","year":"2017","unstructured":"Liss KHH, Finck BN (2017) PPARs and nonalcoholic fatty liver disease. Biochimie 136:65\u201374. https:\/\/doi.org\/10.1016\/j.biochi.2016.11.009","journal-title":"Biochimie"},{"key":"588_CR40","doi-asserted-by":"publisher","first-page":"106786","DOI":"10.1016\/j.phrs.2023.106786","volume":"192","author":"YY Qiu","year":"2023","unstructured":"Qiu YY, Zhang J, Zeng FY, Zhu YZ (2023) Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res 192:106786. https:\/\/doi.org\/10.1016\/j.phrs.2023.106786","journal-title":"Pharmacol Res"},{"key":"588_CR41","doi-asserted-by":"publisher","first-page":"113127","DOI":"10.1016\/j.biopha.2022.113127","volume":"151","author":"J Pan","year":"2022","unstructured":"Pan J, Zhou W, Xu R, Xing L, Ji G, Dang Y (2022) Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. Biomed Pharmacother 151:113127. https:\/\/doi.org\/10.1016\/j.biopha.2022.113127","journal-title":"Biomed Pharmacother"},{"issue":"17","key":"588_CR42","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3748\/wjg.v26.i17.1993","volume":"26","author":"A Katsarou","year":"2020","unstructured":"Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A (2020) Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol 26(17):1993\u20132011. https:\/\/doi.org\/10.3748\/wjg.v26.i17.1993","journal-title":"World J Gastroenterol"},{"issue":"22","key":"588_CR43","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al (2006) A placebo-controlled trial of Pioglitazone in subjects with Nonalcoholic Steatohepatitis. N Engl J Med 355(22):2297\u20132307. https:\/\/doi.org\/10.1056\/NEJMoa060326","journal-title":"N Engl J Med"},{"issue":"18","key":"588_CR44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al (2010) Pioglitazone, vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 362(18):1675\u20131685. https:\/\/doi.org\/10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"588_CR45","doi-asserted-by":"publisher","first-page":"615409","DOI":"10.3389\/fendo.2021.615409","volume":"12","author":"J Lian","year":"2021","unstructured":"Lian J, Fu J (2021) Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes Mellitus: a Meta-analysis. Front Endocrinol 12:615409. https:\/\/doi.org\/10.3389\/fendo.2021.615409","journal-title":"Front Endocrinol"},{"issue":"8","key":"588_CR46","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.3390\/ijms23084305","volume":"23","author":"NF Lange","year":"2022","unstructured":"Lange NF, Graf V, Caussy C, Dufour JF (2022) PPAR-Targeted therapies in the treatment of non-alcoholic fatty liver Disease in Diabetic patients. IJMS 23(8):4305. https:\/\/doi.org\/10.3390\/ijms23084305","journal-title":"IJMS"},{"issue":"17","key":"588_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa203620","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ et al (2021) A Randomized, Controlled Trial of the Pan-PPAR agonist Lanifibranor in NASH. N Engl J Med 385(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa203620","journal-title":"N Engl J Med"},{"issue":"12","key":"588_CR48","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","volume":"19","author":"MS Siddiqui","year":"2021","unstructured":"Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM et al (2021) A phase 2 double Blinded, Randomized Controlled Trial of Saroglitazar in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19(12):2670\u20132672. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.051","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"588_CR49","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","volume":"74","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K et al (2021) Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double\u2010blind phase 2 trial. Hepatology 74(4):1809\u20131824. https:\/\/doi.org\/10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"588_CR50","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.2147\/DDDT.S341223","volume":"15","author":"SH Shuja","year":"2021","unstructured":"Shuja SH, Eqbal F, Rehman H (2021) Saroglitazar\u2013 a potential therapeutic option in Treating NASH? DDDT Volume 15:4227\u20134228. https:\/\/doi.org\/10.2147\/DDDT.S341223","journal-title":"DDDT Volume"},{"key":"588_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS (2019) Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 92:82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014","journal-title":"Metabolism"},{"issue":"6","key":"588_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/obr.12163","volume":"15","author":"A Chatzigeorgiou","year":"2014","unstructured":"Chatzigeorgiou A, Kandaraki E, Papavassiliou AG, Koutsilieris M (2014) Peripheral targets in obesity treatment: a comprehensive update. Obes Rev 15(6):487\u2013503. https:\/\/doi.org\/10.1111\/obr.12163","journal-title":"Obes Rev"},{"key":"588_CR53","unstructured":"FDA Orlistat (marketed as Alli and Xenical) Information. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/orlistat-marketed-alli-and-xenical-information. Accessed 17 August 2023"},{"issue":"6","key":"588_CR54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2036.2004.02153.x","volume":"20","author":"SA Harrison","year":"2004","unstructured":"Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P (2004) A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients: Orlistat in NASH patients. Aliment Pharmacol Ther 20(6):623\u2013628. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02153.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"588_CR55","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","volume":"4","author":"S Zelber\u2013Sagi","year":"2006","unstructured":"Zelber\u2013Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M et al (2006) A double-blind randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4(5):639\u2013644. https:\/\/doi.org\/10.1016\/j.cgh.2006.02.004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"588_CR56","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/hep.22575","volume":"49","author":"SA Harrison","year":"2009","unstructured":"Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49(1):80\u201386. https:\/\/doi.org\/10.1002\/hep.22575","journal-title":"Hepatology"},{"issue":"1","key":"588_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajg.2020.12.005","volume":"22","author":"VAW Esmail","year":"2021","unstructured":"Esmail VAW, Mohammed MO, Al-Nimer MSM (2021) Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab J Gastroenterol 22(1):1\u20135. https:\/\/doi.org\/10.1016\/j.ajg.2020.12.005","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"588_CR58","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/br.2018.1100","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J (2018) Efficacy of orlistat in non\u2013alcoholic fatty liver disease: a systematic review and meta\u2013analysis. Biom Rep 9(1):90\u201396. https:\/\/doi.org\/10.3892\/br.2018.1100","journal-title":"Biom Rep"},{"key":"588_CR59","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada I, Van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ et al (2023) Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. eBioMedicine 87:104392. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104392","journal-title":"eBioMedicine"},{"issue":"15","key":"588_CR60","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","volume":"106","author":"T Sudhop","year":"2002","unstructured":"Sudhop T, L\u00fctjohann D, Kodal A, Igel M, Tribble DL, Shah S et al (2002) Inhibition of intestinal cholesterol absorption by Ezetimibe in humans. Circulation 106(15):1943\u20131948. https:\/\/doi.org\/10.1161\/01.CIR.0000034044.95911.DC","journal-title":"Circulation"},{"issue":"25","key":"588_CR61","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al (2015) Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med 372(25):2387\u20132397. https:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"588_CR62","doi-asserted-by":"publisher","unstructured":"Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J (2004) Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. The American Journal of Cardiology. 2004;93(12):1487\u201394. https:\/\/doi.org\/10.1016\/j.amjcard.2004.02.060","DOI":"10.1016\/j.amjcard.2004.02.060"},{"key":"588_CR63","doi-asserted-by":"publisher","unstructured":"Cho Y, Rhee H, Kim Y, eun, Lee M, Lee BW, Kang ES et al (2022) Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022;20(1):93. https:\/\/doi.org\/10.1186\/s12916-022-02288-2","DOI":"10.1186\/s12916-022-02288-2"},{"issue":"5","key":"588_CR64","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.numecd.2022.01.024","volume":"32","author":"D Noto","year":"2022","unstructured":"Noto D, Petta S, Giammanco A, Spina R, Cabibbi D, Porcasi R et al (2022) Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. Nutr Metabolism Cardiovasc Dis 32(5):1288\u20131291. https:\/\/doi.org\/10.1016\/j.numecd.2022.01.024","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"2","key":"588_CR65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3904\/kjim.2017.194","volume":"34","author":"HY Lee","year":"2019","unstructured":"Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H et al (2019) Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J Intern Med 34(2):296\u2013304. https:\/\/doi.org\/10.3904\/kjim.2017.194","journal-title":"Korean J Intern Med"},{"issue":"4","key":"588_CR66","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10620-021-06955-x","volume":"67","author":"N Noureddin","year":"2022","unstructured":"Noureddin N, Noureddin M, Singh A, Alkhouri N (2022) Progression of nonalcoholic fatty liver Disease-Associated Fibrosis in a large cohort of patients with type 2 diabetes. Dig Dis Sci 67(4):1379\u20131388. https:\/\/doi.org\/10.1007\/s10620-021-06955-x","journal-title":"Dig Dis Sci"},{"key":"588_CR67","doi-asserted-by":"publisher","unstructured":"Mahmoudi A, Moallem SA, Johnston TP, Sahebkar A (2022) Liver Protective Effect of Fenofibrate in NASH\/NAFLD Animal Models. PPAR Res 2022:5805398. https:\/\/doi.org\/10.1155\/2022\/5805398","DOI":"10.1155\/2022\/5805398"},{"key":"588_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trsl.2016.08.006","volume":"180","author":"BH Li","year":"2017","unstructured":"Li BH, He FP, Yang X, Chen YW, Fan JG (2017) Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Translational Res 180:103\u2013117e4. https:\/\/doi.org\/10.1016\/j.trsl.2016.08.006","journal-title":"Translational Res"},{"issue":"3","key":"588_CR69","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","volume":"40","author":"C Fern\u00e1ndez-Miranda","year":"2008","unstructured":"Fern\u00e1ndez-Miranda C, P\u00e9rez-Carreras M, Colina F, L\u00f3pez-Alonso G, Vargas C, Sol\u00eds-Herruzo JA (2008) A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Disease 40(3):200\u2013205. https:\/\/doi.org\/10.1016\/j.dld.2007.10.002","journal-title":"Dig Liver Disease"},{"issue":"12","key":"588_CR70","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/MEG.0000000000000981","volume":"29","author":"M Yaghoubi","year":"2017","unstructured":"Yaghoubi M, Jafari S, Sajedi B, Gohari S, Akbarieh S, Heydari AH et al (2017) Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 29(12):1385\u20131388. https:\/\/doi.org\/10.1097\/MEG.0000000000000981","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"588_CR71","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","volume":"12","author":"J Oscarsson","year":"2018","unstructured":"Oscarsson J, \u00d6nnerhag K, Ris\u00e9rus U, Sund\u00e9n M, Johansson L, Jansson PA et al (2018) Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J Clin Lipidol 12(6):1390\u20131403e4. https:\/\/doi.org\/10.1016\/j.jacl.2018.08.003","journal-title":"J Clin Lipidol"},{"key":"588_CR72","doi-asserted-by":"publisher","first-page":"1073025","DOI":"10.3389\/fmed.2023.1073025","volume":"10","author":"R Sugimoto","year":"2023","unstructured":"Sugimoto R, Iwasa M, Eguchi A, Tamai Y, Shigefuku R, Fujiwara N et al (2023) Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med 10:1073025. https:\/\/doi.org\/10.3389\/fmed.2023.1073025","journal-title":"Front Med"},{"issue":"10","key":"588_CR73","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","volume":"54","author":"A Nakajima","year":"2021","unstructured":"Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H et al (2021) Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 54(10):1263\u20131277. https:\/\/doi.org\/10.1111\/apt.16596","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"588_CR74","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S (2018) Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12(1):173\u2013184. https:\/\/doi.org\/10.1016\/j.jacl.2017.10.006","journal-title":"J Clin Lipidol"},{"issue":"1","key":"588_CR75","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T et al (2021) Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo\u2010controlled clinical trials. Cardiovasc Diabetol 20(1):96. https:\/\/doi.org\/10.1186\/s12933-021-01291-w","journal-title":"Cardiovasc Diabetol"},{"key":"588_CR76","unstructured":"Krupa K, Hapshy V, Nguyen H, Parmar M, Obeticholic A (2023) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567735\/"},{"key":"588_CR77","doi-asserted-by":"publisher","first-page":"109609","DOI":"10.1016\/j.biopha.2019.109609","volume":"121","author":"Y Xi","year":"2020","unstructured":"Xi Y, Li H (2020) Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Biomed Pharmacother 121:109609. https:\/\/doi.org\/10.1016\/j.biopha.2019.109609","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"588_CR78","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W (2008) Farnesoid X receptor antagonizes nuclear factor \u03baB in hepatic inflammatory response. Hepatology 48(5):1632\u20131643. https:\/\/doi.org\/10.1002\/hep.22519","journal-title":"Hepatology"},{"key":"588_CR79","unstructured":"FDA. FDA approves Ocaliva for rare, chronic liver disease (2016) https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-ocaliva-rare-chronic-liver-disease. Accessed 24 August 2023"},{"issue":"9972","key":"588_CR80","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385(9972):956\u2013965. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4","journal-title":"Lancet"},{"issue":"10215","key":"588_CR81","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394(10215):2184\u20132196. https:\/\/doi.org\/10.1016\/S0140-6736(19)33041-7","journal-title":"Lancet"},{"issue":"3","key":"588_CR82","doi-asserted-by":"publisher","first-page":"e0005","DOI":"10.1097\/HC9.0000000000000005","volume":"7","author":"CH Ng","year":"2023","unstructured":"Ng CH, Tang ASP, Xiao J, Wong ZY, Yong JN, Fu CE et al (2023) Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals. Hepatol Commun 7(3):e0005\u2013e0005. https:\/\/doi.org\/10.1097\/HC9.0000000000000005","journal-title":"Hepatol Commun"},{"key":"588_CR83","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","volume":"11","author":"EJ Tillman","year":"2020","unstructured":"Tillman EJ, Rolph T (2020) FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol 11:601290. https:\/\/doi.org\/10.3389\/fendo.2020.601290","journal-title":"Front Endocrinol"},{"issue":"7","key":"588_CR84","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA et al (2021) Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med 27(7):1262\u20131271. https:\/\/doi.org\/10.1038\/s41591-021-01425-3","journal-title":"Nat Med"},{"issue":"1","key":"588_CR85","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C et al (2023) A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep 5(1):100563. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100563","journal-title":"JHEP Rep"},{"issue":"11","key":"588_CR86","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP et al (2023) Randomized, controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med 389(11):998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286","journal-title":"N Engl J Med"},{"key":"588_CR87","doi-asserted-by":"publisher","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","volume":"11","author":"E Henriksson","year":"2020","unstructured":"Henriksson E, Andersen B (2020) FGF19 and FGF21 for the treatment of NASH\u2014Two sides of the same Coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Front Endocrinol 11:601349. https:\/\/doi.org\/10.3389\/fendo.2020.601349","journal-title":"Front Endocrinol"},{"issue":"5","key":"588_CR88","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.3390\/ijms24054583","volume":"24","author":"H Tian","year":"2023","unstructured":"Tian H, Zhang S, Liu Y, Wu Y, Zhang D (2023) Fibroblast growth factors for nonalcoholic fatty liver disease: opportunities and challenges. Int J Mol Sci 24(5):4583. https:\/\/doi.org\/10.3390\/ijms24054583","journal-title":"Int J Mol Sci"},{"issue":"1","key":"588_CR89","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","volume":"160","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP et al (2021) Efficacy and safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 160(1):219\u2013231e1. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.004","journal-title":"Gastroenterology"},{"issue":"3","key":"588_CR90","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","volume":"79","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lieu HD, Kowdley KV, Goodman ZD, Alkhouri N, Lawitz E et al (2024) A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 79(3):674\u2013689. https:\/\/doi.org\/10.1097\/HEP.0000000000000607","journal-title":"Hepatology"},{"issue":"1","key":"588_CR91","doi-asserted-by":"publisher","first-page":"15661","DOI":"10.1038\/s41598-022-19459-z","volume":"12","author":"M O\u2019Farrell","year":"2022","unstructured":"O\u2019Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D et al (2022) FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci Rep 12(1):15661. https:\/\/doi.org\/10.1038\/s41598-022-19459-z","journal-title":"Sci Rep"},{"issue":"5","key":"588_CR92","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","volume":"161","author":"R Loomba","year":"2021","unstructured":"Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF et al (2021) TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology 161(5):1475\u20131486. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.025","journal-title":"Gastroenterology"},{"issue":"7","key":"588_CR93","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/gb-2005-6-7-226","volume":"6","author":"P Wang","year":"2005","unstructured":"Wang P, Heitman J (2005) The cyclophilins. Genome Biol 6(7):226. https:\/\/doi.org\/10.1186\/gb-2005-6-7-226","journal-title":"Genome Biol"},{"issue":"12","key":"588_CR94","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1002\/hep4.2100","volume":"6","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Mayo PR, Hobbs TM, Canizares C, Foster EP, Zhao C et al (2022) Rencofilstat, a cyclophilin inhibitor: a phase 2a, multicenter, single-blind, placebo\u2010controlled study in F2\/F3 NASH. Hepatol Commun 6(12):3379\u20133392. https:\/\/doi.org\/10.1002\/hep4.2100","journal-title":"Hepatol Commun"},{"issue":"7","key":"588_CR95","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/glycob\/cwj088","volume":"16","author":"PJ Davidson","year":"2006","unstructured":"Davidson PJ, Li SY, Lohse AG, Vandergaast R, Verde E, Pearson A et al (2006) Transport of galectin-3 between the nucleus and cytoplasm. I. conditions and signals for nuclear import. Glycobiology 16(7):602\u2013611. https:\/\/doi.org\/10.1093\/glycob\/cwj088","journal-title":"Glycobiology"},{"issue":"5","key":"588_CR96","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M et al (2020) Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic Steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158(5):1334\u20131345e5. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.296","journal-title":"Gastroenterology"},{"issue":"2","key":"588_CR97","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4254\/wjh.v15.i2.201","volume":"15","author":"M Kram","year":"2023","unstructured":"Kram M (2023) Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 15(2):201\u2013207. https:\/\/doi.org\/10.4254\/wjh.v15.i2.201","journal-title":"World J Hepatol"},{"issue":"11\u201312","key":"588_CR98","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/apt.13816","volume":"44","author":"SA Harrison","year":"2016","unstructured":"Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA et al (2016) Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther 44(11\u201312):1183\u20131198. https:\/\/doi.org\/10.1111\/apt.13816","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"588_CR99","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke F, Puengel T, Loomba R, Friedman SL (2023) An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol 79(2):552\u2013566. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038","journal-title":"J Hepatol"},{"issue":"12","key":"588_CR100","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","volume":"12","author":"R Safadi","year":"2014","unstructured":"Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T et al (2014) The fatty acid\u2013bile Acid Conjugate Aramchol reduces Liver Fat Content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12(12):2085\u20132091e1. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.038","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"588_CR101","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/hep.30674","volume":"70","author":"VH Ajmera","year":"2019","unstructured":"Ajmera VH, Cachay E, Ramers C, Vodkin I, Bassirian S, Singh S et al (2019) MRI Assessment of Treatment Response in HIV-associated NAFLD: a Randomized Trial of a stearoyl\u2010Coenzyme\u2010A\u2010Desaturase\u20101 inhibitor (ARRIVE trial). Hepatology 70(5):1531\u20131545. https:\/\/doi.org\/10.1002\/hep.30674","journal-title":"Hepatology"},{"issue":"10","key":"588_CR102","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","volume":"27","author":"V Ratziu","year":"2021","unstructured":"Ratziu V, De Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J et al (2021) Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 27(10):1825\u20131835. https:\/\/doi.org\/10.1038\/s41591-021-01495-3","journal-title":"Nat Med"},{"key":"588_CR103","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.2147\/DDDT.S315724","volume":"15","author":"JM Fraile","year":"2021","unstructured":"Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M (2021) Non-alcoholic Steatohepatitis (NASH) - a review of a crowded Clinical Landscape, driven by a Complex Disease. Drug Des Devel Ther 15:3997\u20134009. https:\/\/doi.org\/10.2147\/DDDT.S315724","journal-title":"Drug Des Devel Ther"},{"key":"588_CR104","unstructured":"FDA (2024) FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed 10 May 2024"},{"issue":"10213","key":"588_CR105","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394(10213):2012\u20132024. https:\/\/doi.org\/10.1016\/S0140-6736(19)32517-6","journal-title":"Lancet"},{"key":"588_CR106","unstructured":"Madrigal P (2022) Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis. https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-announces-positive-topline-results-pivotal-phase-3. Accessed 29 August 2023"},{"issue":"6","key":"588_CR107","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R et al (2024) A phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"2","key":"588_CR108","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12072-018-9854-1","volume":"12","author":"AJ Kovalic","year":"2018","unstructured":"Kovalic AJ, Satapathy SK, Chalasani N (2018) Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. Hepatol Int 12(2):97\u2013106. https:\/\/doi.org\/10.1007\/s12072-018-9854-1","journal-title":"Hepatol Int"},{"issue":"7","key":"588_CR109","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/ijms20071634","volume":"20","author":"A Puente","year":"2019","unstructured":"Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Llerena S et al (2019) LOXL2-A New Target in Antifibrogenic Therapy? Int J Mol Sci 20(7):1634. https:\/\/doi.org\/10.3390\/ijms20071634","journal-title":"Int J Mol Sci"},{"issue":"2","key":"588_CR110","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H et al (2018) The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 67(2):549\u2013559. https:\/\/doi.org\/10.1002\/hep.29514","journal-title":"Hepatology"},{"issue":"1","key":"588_CR111","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VWS, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z et al (2020) Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 73(1):26\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.027","journal-title":"J Hepatol"},{"issue":"4","key":"588_CR112","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R et al (2018) Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by Nonalcoholic Steatohepatitis. Gastroenterology 155(4):1140\u20131153. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.006","journal-title":"Gastroenterology"},{"key":"588_CR113","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","volume":"64","author":"E Scorletti","year":"2018","unstructured":"Scorletti E, Byrne CD (2018) Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action. Mol Aspects Med 64:135\u2013146. https:\/\/doi.org\/10.1016\/j.mam.2018.03.001","journal-title":"Mol Aspects Med"},{"issue":"9","key":"588_CR114","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3390\/nu12092769","volume":"12","author":"CH Lee","year":"2020","unstructured":"Lee CH, Fu Y, Yang SJ, Chi CC (2020) Effects of Omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: a systematic review and Meta-analysis. Nutrients 12(9):2769. https:\/\/doi.org\/10.3390\/nu12092769","journal-title":"Nutrients"},{"issue":"4","key":"588_CR115","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.12669\/pjms.334.12315","volume":"33","author":"L Yu","year":"2017","unstructured":"Yu L, Yuan M, Wang L (2017) The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: a systematic review and meta-analysis of RCTs. Pak J Med Sci 33(4):1022\u20131028. https:\/\/doi.org\/10.12669\/pjms.334.12315","journal-title":"Pak J Med Sci"},{"key":"588_CR116","doi-asserted-by":"publisher","first-page":"1005312","DOI":"10.3389\/fphar.2022.1005312","volume":"13","author":"P Tan","year":"2022","unstructured":"Tan P, Jin L, Qin X, He B (2022) Natural flavonoids: potential therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol 13:1005312. https:\/\/doi.org\/10.3389\/fphar.2022.1005312","journal-title":"Front Pharmacol"},{"key":"588_CR117","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jnutbio.2018.10.001","volume":"65","author":"M Mazidi","year":"2019","unstructured":"Mazidi M, Katsiki N, Banach M (2019) A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study. J Nutr Biochem 65:66\u201371. https:\/\/doi.org\/10.1016\/j.jnutbio.2018.10.001","journal-title":"J Nutr Biochem"},{"issue":"3","key":"588_CR118","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cld.2004.04.012","volume":"8","author":"AM Diehl","year":"2004","unstructured":"Diehl AM (2004) Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 8(3):619\u2013638. https:\/\/doi.org\/10.1016\/j.cld.2004.04.012","journal-title":"Clin Liver Dis"},{"issue":"2","key":"588_CR119","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","volume":"20","author":"J Du","year":"2014","unstructured":"Du J, Ma YY, Yu CH, Li YM (2014) Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 20(2):569\u2013577. https:\/\/doi.org\/10.3748\/wjg.v20.i2.569","journal-title":"World J Gastroenterol"},{"issue":"2","key":"588_CR120","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2):367\u2013378e5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"588_CR121","doi-asserted-by":"publisher","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S et al (2021) Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2029349","DOI":"10.1056\/NEJMoa2029349"},{"key":"588_CR122","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2018) Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. https:\/\/www.fda.gov\/media\/119044\/download. Accessed 22 August 2023"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00588-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-024-00588-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00588-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:13:01Z","timestamp":1730110381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-024-00588-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s42000-024-00588-1","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}